Skip to Content
Merck
CN
  • High expression of tight junction protein 1 as a predictive biomarker for bladder cancer grade and staging.

High expression of tight junction protein 1 as a predictive biomarker for bladder cancer grade and staging.

Scientific reports (2022-01-29)
Yi-Chen Lee, Kuo-Wang Tsai, Jia-Bin Liao, Wei-Ting Kuo, Yu-Chan Chang, Yi-Fang Yang
ABSTRACT

Tight junction proteins 1-3 (TJP1-3) are components of tight junctions that can link transmembrane proteins to the actin cytoskeleton, and their incidence directly correlates to metastasis. However, the role of the TJP family in bladder cancer has not been adequately evaluated. In this study, we evaluated the genetic changes, mRNA and protein expressions of the target genes of the TJP family in bladder cancer patients using online database and immunohistochemistry, respectively. We found that TJP1 was amplified in bladder cancer tissue and that the protein expression levels were significantly associated with age (p = 0.03), grade (p = 0.007), and stage (p = 0.011). We also examined the correlation between TJP1 and other high-frequency mutation genes using TIMER. TJP1 mRNA levels were positively correlated with TTN and RYR3 mRNA levels in bladder cancer tissue. Taken together, TJP1 expression is associated with poor clinical outcomes in patients with bladder cancer and can be a useful predictive biomarker for bladder cancer staging.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-TJP1 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution